Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ermium Therapeutics

Explore full profile

Developing innovative therapies for auto-immune diseases, based on a breakthrough discovery

Paris, FranceFounded 2019Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2022
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Ermium Therapeutics and the history behind them.

About Ermium Therapeutics

Ermium Therapeutics is a biotechnology company focused on developing groundbreaking therapies for autoimmune diseases. The company operates in the healthcare and biotechnology market, primarily serving patients suffering from autoimmune conditions. Ermium's business model revolves around leveraging a breakthrough discovery that identifies CXCR4 as a master regulator of inflammation, which is pivotal in the development of autoimmune diseases.

Read full description

Ermium Therapeutics generates revenue through the development and commercialization of its innovative therapies. The company has secured significant funding, including a Series A round, to advance its research and development efforts. Additionally, Ermium has executed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes, facilitated by Erganeo, which underscores its strong academic and research foundation.

Ermium's clientele includes healthcare providers, research institutions, and patients who benefit from its cutting-edge treatments. The company aims to transform the landscape of autoimmune disease treatment by offering targeted therapies that address the root causes of inflammation.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
Paris, France
Sector
Biotech & Life Sciences

Latest news

Press, funding announcements and product moves mentioning Ermium Therapeutics.

See all news

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Kurma Partners
  • Domain Therapeutics
  • Eurazeo
  • Fountain Healthcare Partners

Talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇫🇷 France · Paris HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ermium Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ermium Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles